Cargando…

Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling

BACKGROUND: Heterogeneous efficacy of neoadjuvant chemotherapy has led to controversies that have limited its application in clinical practice. Thus, we aimed to identify potential biomarkers predicting esophageal squamous cell carcinoma (ESCC) chemo-responsiveness by gene expression profiling. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Lu-Yan, Wang, Hui, Dong, Bin, Yan, Wan-Pu, Lin, Yao, Shi, Qi, Chen, Ke-Neng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826224/ https://www.ncbi.nlm.nih.gov/pubmed/26673820 http://dx.doi.org/10.18632/oncotarget.6554

Ejemplares similares

Downregulation of HOXA13 sensitizes human esophageal squamous cell carcinoma to chemotherapy
por: Shi, Qi, et al.
Publicado: (2018)

Efficacy of postoperative adjuvant chemotherapy for esophageal squamous cell carcinoma: A meta‐analysis
por: Zhao, Peiliang, et al.
Publicado: (2018)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

The Role of Adjuvant Chemotherapy in the Treatment of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemotherapy
por: Li, Keting, et al.
Publicado: (2023)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma
por: Wu, Zhigang, et al.
Publicado: (2021)

Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta‐analysis
por: Fan, Mengying, et al.
Publicado: (2015)

Immuno-genomic profiling of biopsy specimens predicts neoadjuvant chemotherapy response in esophageal squamous cell carcinoma
por: Sasagawa, Shota, et al.
Publicado: (2022)

Targeting HOX/PBX dimer formation as a potential therapeutic option in esophageal squamous cell carcinoma
por: Shen, Lu‐Yan, et al.
Publicado: (2019)

Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Gu, Yi-Min, et al.
Publicado: (2022)

Stratified treatment of localized cervical esophageal squamous cell carcinoma induced by neoadjuvant immunotherapy plus chemotherapy (SCENIC)
por: Li, Chunguang, et al.
Publicado: (2022)

Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma
por: Ma, Shaohua, et al.
Publicado: (2018)

Effect of Body Composition Change during Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Onishi, Sachiyo, et al.
Publicado: (2022)

Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
por: Lv, Huilai, et al.
Publicado: (2022)

Distribution of residual tumors in esophageal squamous cell carcinoma after neoadjuvant PD-1 blockade combined with chemotherapy
por: Jiang, Dongxian, et al.
Publicado: (2023)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909)
por: Zheng, Yan, et al.
Publicado: (2021)

Neoadjuvant chemoradiotherapy plus surgery in the treatment of potentially resectable thoracic esophageal squamous cell carcinoma
por: Yan, Mao-Hui, et al.
Publicado: (2020)

Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial
por: Wang, Hao, et al.
Publicado: (2021)

Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
por: Loc, Nguyen Vo Vinh, et al.
Publicado: (2023)

Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis
por: Guo, Yaru, et al.
Publicado: (2022)

Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
por: Liu, Jun, et al.
Publicado: (2022)

Pattern of tumor regression after neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma
por: Li, Bin, et al.
Publicado: (2023)

Clinical value of hematologic test in predicting tumor response to neoadjuvant chemotherapy with esophageal squamous cell carcinoma
por: Liu, Yinan, et al.
Publicado: (2014)

Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Yang, Guozhen, et al.
Publicado: (2021)

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
por: Yang, Weixiong, et al.
Publicado: (2022)

The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma
por: Park, Seong Yong, et al.
Publicado: (2023)

Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Perioperative and Survival Outcomes
por: Ma, Xiao, et al.
Publicado: (2022)

A phase II, single-centre trial of neoadjuvant toripalimab plus chemotherapy in locally advanced esophageal squamous cell carcinoma
por: Xing, Wenqun, et al.
Publicado: (2020)

Deregulated HOXB7 Expression Predicts Poor Prognosis of Patients with Esophageal Squamous Cell Carcinoma and Regulates Cancer Cell Proliferation In Vitro and In Vivo
por: Li, Hui, et al.
Publicado: (2015)

Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials Over the Past 20 Years
por: Zheng, Yan, et al.
Publicado: (2015)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy
por: Niwa, Yukiko, et al.
Publicado: (2019)

GR, Sgk1, and NDRG1 in esophageal squamous cell carcinoma: their correlation with therapeutic outcome of neoadjuvant chemotherapy
por: Ueki, Shunsuke, et al.
Publicado: (2020)

Clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy
por: Okuda, Sho, et al.
Publicado: (2022)

Neutrophil-to-lymphocyte ratio after neoadjuvant chemotherapy as an independent prognostic factor in patients with esophageal squamous cell carcinoma
por: Yamada, Moyuru, et al.
Publicado: (2022)

Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study
por: Zhao, Junfeng, et al.
Publicado: (2023)

Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching
por: Jing, Shao-Wu, et al.
Publicado: (2022)

Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial
por: Zhang, Zhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t5296q8lhss8e41eq3sg78eoa3